Fezolinetant for hot flashes in men on hormone therapy
Part of Cancer, Genetic & congenital, Hormones & metabolism, Kidney & urinary clinical trials.
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man diagnosed with prostate cancer.
- You must be 40 years of age or older.
- You must be receiving androgen deprivation therapy (hormone therapy to lower testosterone).
- You must have at least 5 moderate to severe hot flashes per day or 35 per week.
- You must be willing to abstain from alcohol for the duration of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a wearable cooling or heating device can help reduce hot flashes caused by hormone therapy for prostate cancer. You will use the device for 12 weeks and report how often and how much your hot flashes bother you.
This study tests whether fezolinetant can reduce hot flushes in men receiving hormone therapy (ADT) for prostate cancer. If you have bothersome hot flushes, this treatment may help lessen them.
This trial tests a non-hormonal pill called fezolinetant to reduce hot flashes in men with prostate cancer who are on hormone therapy. If you have daily, bothersome hot flashes, this study may help you find relief.
This study tests a non-hormonal pill called fezolinetant to see if it reduces hot flashes in Indian women going through menopause. It may offer a new option for women who cannot or prefer not to use hormone therapy.
This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.
This study looks at how a new medicine called fezolinetant is processed by the body when taken alongside common prostate cancer hormone treatments. It is an early-phase trial that helps researchers understand if there are any drug interactions, which could be important for future treatment options.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.